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Background: The novel pandemic A (H1N1) pdm09 virus was first identified in Mexico in April 2009 and since then
it spread worldwide over a short period of time. Although the virus infection is generally associated with mild
disease and a relatively low mortality, it is projected that mutations in specific regions of the viral genome,
especially within the receptor binding domain of the haemagglutinin (HA) protein could result in more virulent
virus stains, leading to a more severe pathogenicity.
Methods: To monitor the genetic polymorphisms at position 222 of Haemagglutinin of influenza A(H1N1)pdm09
viruses from both outpatients with mild influenza and individuals with severe disease requiring hospitalization,
during 2009–2010 and 2010–2011 seasons, a sequence-based genotypic assessment of viral populations to
understand the prevalence of D222G mutation.
Results: The D222G was identified in clinical specimens from 3 out of 42 cases analyzed in Tunisia with severe
outcome (7%). Interestingly, in one fatal case out of four viruses taken from fatal cases studied (25%). Also this
mutation was found in one mild case out of 8 mild cases studied (0.1%). D222E substitution was found in virus
taken from one patient with severe clinical syndrome (2%) out of 42 severe cases analyzed and E374K substitution
was found in two severe cases (4%) out of 42 severe cases studied.
Conclusions: A specific mutation in the viral haemagglutinin (D222G) was found in fatal, severe and mild case.
Further virological, clinical and epidemiological investigations are needed to ascertain the role of this and other
mutations that may alter the virulence and transmissibility of the pandemic influenza A (H1N1)pdm09.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1027334947811255
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infectionIntroduction
In April 2009, a novel swine-derived influenza A(H1N1)
pdm09 emerged and spread rapidly around the world
[1,2], causing the World Health Organization to declare a
pandemic in June. Since the first appearance of influenza
A(H1N1)pdm09, one particular amino acid substitution
{aspartic acid to glycine at position 222 (D222G)} (225 in* Correspondence: jledesmam@yahoo.es
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reproduction in any medium, provided the orH3 numbering) within the hemagglutinin (HA) molecule
has appeared sporadically in 20 countries, including
Norway, Mexico, Ukraine and the USA [3-5]. The D222G
substitution is known to cause a shift from α2,6-SA recep-
tor specificity to mixed α2,3/α2,6-sialic acid receptor spe-
cificity [6,7]. It is noteworthy that is highly conserved
among avian viruses [8]. Previously, α2,3-specific avian vi-
ruses have been isolated from patients during the initial
phases of the pandemics of 1957 and 1968, and avian HA
in humans has been shown to be selected for increased
affinity for the α2,6 receptor [8]. Also, the substitution wasral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the existence and transmissibility of influenza A(H1N1)
pdm09 α2,3-SA specific viruses remain unclear. To iden-
tify whether α2,3-SA specific viruses, which replicate well
in swine, were spread during the early phase of the pan-
demic and whether α2,3-SA specific viruses are easily
transmitted, the nucleotide sequences of the HA receptor
binding site of influenza A(H1N1)pdm09 in clinical speci-
mens were determined in this study.
In an attempt to understand the relevance of HA
D222G substitution among influenza A(H1N1)pdm09
causing infections in Tunisia, HA gene sequences from re-
spiratory specimens of severe and non-severe cases were
examined. In addition to the D222G substitution, we fo-
cused on another substitution {glutamic acid 374 to lysine
acid (E374K)}, mutation located at the stalk of HA2 in the
cavity where the fusion domain of mature HA molecules
might have an impact on the antigenicity or neutralization
activity of influenza A(H1N1)pdm09 [10-12].
Material and methods
Nasopharyngeal or throat swab specimens from influenza
patients are received directly from sentinel primary care
physicians participating in virological surveillance schemes
in the community. Samples are also received from com-
munity, hospitalised and fatal cases are forwarded to the
Tunisia National Influenza Centre for diagnostic and
further characterisation. A total of 7350 specimens from
influenza patients were collected in Tunisia during 2009–
2010 season and 894 specimens during 2010–2011 season.
The samples used in this study were taken from 50
patients including 42 respiratory specimens from severe
(patients hospitalized with severe pneumonia and severe
acute respiratory syndrome) and fatal cases, as well as
from 8 cases with mild clinical outcomes. Mild cases
presented with at least one of the following influenza-
like illness symptoms: fever of at least 38°C, cough,
rhinorrhea, headache, or abdominal symptoms (i.e., diar-
rhea and vomiting).
Viral RNA was extracted from respiratory samples
(Oro-pharyngeal and nasopharyngeal swabs) using com-
mercially available QIAamp Viral RNA Mini Kit QIAGEN
as per manufacturer’s instructions. For initial detection of
Influenza A virus, amplification of matrix protein (M)
gene was carried by real time RT-PCR CDC protocol [13].
For subtyping of Influenza A positive samples, the HA
gene (segment 4) of influenza A(H1N1)pdm09 viruses
were analyzed by specific real-time PCR using “Influenza
virus A 1 Real Time RT-PCR Kit” (Shanghai ZJ Bio-Tech
Co. Ltd). In order to identify the Changes in HA amino
acid diversity in individual cases, genetic characterisation
is performed by targeted haemagglutinin (HA) sequence
analysis and/or partial genome (931 nucleotide residues)
sequencing for a subset of isolates. All viruses analyzedwere amplified and sequenced according to the protocol
of National Influenza Centre Madrid [14]. Primers PHA1+
(5’-GGGGTTAGCAAAAGCAGGRG-3’) and PHA1− (5’-
CAWCCRKCIAYCAKICCWKICCAICC-3’) were used for
RT-PCR and H1 + SSEQB (5’-AAYAAYTCIACYGACAC
TG-3’) and H1-ASEQ (5’-CCCTCAATRAAACCRGCA
AT-3’) for nested PCR.
The sequences were analyzed using the maximum
composite likelihood method and the MEGA version 4.0
software package with 500 bootstrap replicates [15].
Nucleotide sequence accession numbers: The nucleotide
sequences of HA determined in this study can be found
in GenBank databases under the indicated accession
numbers JN037697 to JN037779 (http://WWW.ncbi.nih.
gov/genomes/FLU/SwineFlu.html).
Ethical approval
The ethical aspects of this study were approved by
Charles Nicolle's Hospital ethic committee.
Results
During the pandemic year, a total of 3836 out of 7350
respiratory specimens with ILI coming from the sentinel
physicians network were positive for influenza A(H1N1)
pdm (95%). In 2010–2011 season, 146 out of 894 of the
cases were positive for influenza A(H1N1)pdm09 (70%).
Here we report the occurrence of an amino acid substi-
tution, aspartic acid to glycine in position 222 (D222G)
in the HA subunit of the viral haemagglutinin, in clinical
specimens from 3 out of 42 cases analyzed in Tunisia
with severe outcome (7%). Interestingly, in one fatal case
out of four viruses taken from fatal cases studied (25%).
This patient died after 3 days, suffering of severe respira-
tory symptoms of flu. Autopsy revealed pulmonary
oedema, large mucosis secretions but no cardiac inflam-
mation (Table 1). Also this mutation was found in one
mild case out of 8 mild cases studied (0.1%). Moreover,
D222E was found in one out of 50 viruses studied. This
mutation was found in virus taken from one patient with
severe clinical syndrome out of 42 severe cases studied
(2%). E374K substitution was found in two severe cases
(4%). This analysis of HA also showed frequent substitu-
tions in other positions. P83S and S203T were detected
in 94% of Tunisian viruses studied.
Discussion
Genetic analysis of HA of influenza A (H1N1)pdm09
virus showed that this virus was a reassortant containing
gene segments from ancestor viruses of human, swine
and avian sources. Hence, Polymorphism at position 222
within the haemagglutinin (HA) molecule may have
remarkable impact on viral host range, replication, and
pathogenicity. It is worth noting that although the
Table 1 Characteristics of patients according to the outcome of the infections and molecular analysis






Mutation Age Sex Clinical information
A/Tunisia/20043/2009 12/12/2009 JN037731 K374E 33 Male Severe pneumonia
A/Tunisia/20112/2009 14/12/2009 JN037733 D222E 43 Male Severe pneumonia with acute respiratory
syndrome
A/Tunisia/1064/2010 18/01/2010 HM590676 D222G 47 Male Severe pneumonia and death
A/Tunisia/197/2011 04/01/2011 CY080589 K374E 46 Female Severe pneumonia
A/Tunisia/1411/2011 7/02/2011 JN037741 D222G 15 Male Mild case
A/Tunisia/1701/2011 10/02/2011 JN037743 D222G 45 Male Severe pneumonia requiring intensive care
D, aspartic acid; G, glycine; E, glutamic acid; K, lysine.
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with severe pandemic in humans.
An association between D222G and severity was initially
proposed by Kilander et al. (2010) [16] and, since then,
different studies in several countries [17] have found the
D222G substitution to be more frequently associated with
patients with severe pandemic influenza than in non-
severe control cases. A recent study supported a role for
this mutation in allowing the virus access to deeper lung
tissue [18]. Hese unusual viral attributes suggested that
this new virus may possess some virulence characteristics
similar to the highly pathogenic H5N1 or the 1918 pan-
demic influenza viruses.
This study used a conventional sequencing approach
to analyze 50 H1N1pdm samples obtained from 2009 to
2011. Viruses with D222G substitution in HA protein
have appeared sporadically and spontaneously in Tunisia
since July 2009 [19]. Although, 7% of them, found in se-
vere cases in the present study, had the D222G substitu-
tion. This percentage is comparable to that found in
Italy (4%) [5], in United Kingdom (6%) [17], in France
(8%) [20] or in Spain (5%) [14], and lower than that pub-
lished in Norway (18%) [16], and in Hong Kong (17.4%)
[21]. These differences with the Norwegian and Chinese
study might be due to the reduced number of severe
cases analyzed in that country. In Tunisia, this mutation
was observed in circulating virus obtained from severe
cases [19] and also from mild cases. The frequency of
D222G substitution is higher in severe cases than mild
cases. Although most of studies demonstrated the pres-
ence of D222G substitution in severe cases, it was also
reported in mild cases [5,22]. Therefore, the number of
mild cases would need to be larger to determine whether
mutant viruses are indeed circulating at a very low fre-
quency also in non-severe cases.
The 222 G/E polymorphisms in the haemagglutinin
(HA) gene of influenza A(H1N1)pdm09 virus have been
associated with cases of mild to severe illness from dif-
ferent countries or geographical areas [23]. Many retro-
spective analyses have found that cases bearing the
D222G mutation were more likely to be associated withsevere pneumonia, admission to intensive care facilities,
and death [24]. The majority of studies have reported
that presence of D222G is sufficient to enhance virus
replication and lethality in mouse models, with this effect
ranging from modest to pronounced [25,26]. Moreover,
D222G substitution had been present in the Tunisian virus
strain since pandemic season and throughout 2010–2011
season. Other groups have not observed substantial differ-
ences between wild-type and D222G viruses in mouse or
ferret models [6], indicating the need for further investiga-
tion into the role of D222G in virulence of influenza A
(H1N1)pdm09. The D222E was detected with less fre-
quency than the D222G and only found in severe case
patient. Despite the available virological, epidemio-
logical and clinical information, the D222E substitution
could confer more severity to the disease. The clinical
significance of this mutation is still unclear [27]. All
above studies demonstrated that polymorphism of the
HA protein, especially within the receptor binding
domain, play a critical role in the binding preference
and pathogenicity of influenza A(H1N1)pdm09 virus.
Further study is warranted to elucidate the intriguing
relationship between D222G substitution and severe
disease.Conclusion
Whether the selection of the D222G mutation is a cause
or a consequence of more severe lower respiratory tract
infection is still to be resolved. It is evident, however, that
its emergence is likely to exacerbate the severity of disease.
The altered receptor specificity and distinctive cell tropism
of the D222G mutants of influenza A(H1N1)pdm09 are
hallmarks of a more dangerous pathogen, emphasizing
the importance of close monitoring of the evolution of
these viruses. Influenza A(H1N1)pdm09 variants with
222 G/E polymorphisms showed increased clinical viru-
lence, and detection of such mutants in the next epi-
demics is mandatory for better management of ILI in
individual patients as well as for surveillance purposes
especially in African countries.
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